CoChat

Invasive pulmonary aspergillosis in the COVID‐19 era: An expected new entity

Open access
Machado, Marina, Valerio, Maricela, Álvarez‐Uría, Ana, Olmedo, María, Veintimilla, Cristina, Padilla, Belén, De la Villa, Sofía, Guinea, Jesús, Escribano, Pilar, Ruiz‐Serrano, María Jesús, Reigadas, Elena, Alonso, Roberto, Guerrero, José Eugenio, Hortal, Javier, Bouza, Emilio, Muñoz, Patricia, the COVID‐19 Study Group · 2021 · Mycoses
Cited by 203

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Objectives: Information on the recently COVID‐19‐associated pulmonary aspergillosis (CAPA) entity is scarce. We describe eight CAPA patients, compare them to colonised ICU patients with coronavirus disease 2019 (COVID‐19), and review the published literature from Western countries. Methods: Prospective study (March to May, 2020) that included all COVID‐19 patients admitted to a tertiary hospital. Modified AspICU and European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) criteria were used. Results: COVID‐19‐associated pulmonary aspergillosis was diagnosed in eight patients (3.3% of 239 ICU patients), mostly affected non‐immunocompromised patients (75%) with severe acute respiratory distress syndrome (ARDS) receiving corticosteroids. Diagnosis was established after a median of 15 days under mechanical ventilation. Bronchoalveolar lavage was performed in two patients with positive Aspergillus fumigatus cultures and galactomannan (GM) index. Serum GM was positive in 4/8 (50%). Thoracic CT scan findings fulfilled EORTC/MSG criteria in one case. Isavuconazole was used in 4/8 cases. CAPA‐related mortality was 100% (8/8). Compared with colonised patients, CAPA subjects were administered tocilizumab more often (100% vs. 40%, p = .04), underwent longer courses of antibacterial therapy (13 vs. 5 days, p = .008), and had a higher all‐cause mortality (100% vs. 40%, p = .04). We reviewed 96 similar cases from recent publications: 59 probable CAPA (also putative according modified AspICU), 56 putative cases and 13 colonisations according AspICU algorithm; according EORTC/MSG six proven and two probable. Overall, mortality in the reviewed series was 56.3%. Conclusions: COVID‐19‐associated pulmonary aspergillosis must be considered a serious and potentially life‐threatening complication in patients with severe COVID‐19 receiving immunosuppressive treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/myc.13213

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 203

Metadata

Authors
Machado, M., Valerio, M., Álvarez‐Uría, A., Olmedo, M., Veintimilla, C., Padilla, B., De la Villa, S., Guinea, J., Escribano, P., Ruiz‐Serrano, M. J., Reigadas, E., Alonso, R., Guerrero, J. E., Hortal, J., Bouza, E., Muñoz, P., & the COVID‐19 Study Group
Venue
Mycoses
Publisher
Wiley
Published
2020-11-29
Volume
64
Issue
2
Pages
132-143
ISSN
  • 0027-5557 (ISSN-L)
  • 0933-7407
  • 1439-0507
OpenAlex
W3099019571
Cited by
203
References
5
FWCI
5.22
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Invasive pulmonary aspergillosis in the COVID‐19 era: An expected new entity. https://app.cochat.ai/papers/10.1111/myc.13213
The paper
Machado, M., Valerio, M., Álvarez‐Uría, A., Olmedo, M., Veintimilla, C., Padilla, B., De la Villa, S., Guinea, J., Escribano, P., Ruiz‐Serrano, M. J., Reigadas, E., Alonso, R., Guerrero, J. E., Hortal, J., Bouza, E., Muñoz, P., & the COVID‐19 Study Group. (2021). Invasive pulmonary aspergillosis in the COVID‐19 era: An expected new entity. Mycoses. https://doi.org/10.1111/myc.13213

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.